Vanadate, molybdate and tungstate for orthomolecular medicine.
Recent studies indicate that oxyanions, such as vanadate (V) or vanadyl (IV), cause insulin-like effects on rats by stimulating the insulin receptor tyrosine kinase. Tungstate (VI) and molybdate (VI) show the same effects on rat adipocytes and hepatocytes. Results of uncontrolled trials on volunteers accumulated in Japan also suggest that tungstate effectively regulates diabetes mellitus without detectable side effects. Since these oxyanions naturally exist in organisms, oxyanion therapy, the oral administration of vanadate, vanadyl, molybdate, or tungstate, can be considered to be orthomolecular medicine. Therefore, these oxyanions may provide a viable alternative to chemotherapy. Many diseases in addition to diabetes mellitus might also be treated since the implication of these results is that tyrosine kinases are involved in a variety of diseases.
Matsumoto
J
J
Department of Chemistry, University of Massachusetts, Amherst 01002.
D017667:Adipocytes / Q000187:drug effects; D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy; D006801:Humans; D008099:Liver / Q000166:cytology / Q000187:drug effects; D008982:Molybdenum / Q000494:pharmacology / Q000627:therapeutic use*; D009974:Orthomolecular Therapy; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D051381:Rats; D011972:Receptor, Insulin / Q000378:metabolism; D017973:Tungsten Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D014638:Vanadates / Q000494:pharmacology / Q000627:therapeutic use*
D017973:Tungsten Compounds; C044659:molybdate; D014638:Vanadates; D008982:Molybdenum; D011505:Protein-Tyrosine Kinases; D011972:Receptor, Insulin; C045951:tungstate